EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation

Mohamed Salla iD, Jimmy Guo, Harshad Joshi, Marilyn Gordon, Hitesh Dooky, Justine Lai iD, Samantha Capicio, Heather Armstrong iD, Rosica Valcheva, Jason R B Dyck iD, Aducio Thiesen iD, Eytan Wine iD und 2 weitere

International Journal of Molecular Sciences · 22.03.2023 · 24 (6) · 5967

DOI: 10.3390/ijms24065967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.03.2023. Verfasst von Mohamed Salla und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Inflammatory Bowel Diseases, Colitis, Ulcerative. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Innovates, Alberta Innovates-Health solutions cancer CRIO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent inflammation can trigger altered epigenetic, inflammatory, and bioenergetic states. Inflammatory bowel disease (IBD) is an idiopathic disease characterized by chronic inflammation of the gastrointestinal tract, with evidence of subsequent metabolic syndrome disorder. Studies have demonstrated that as many as 42% of patients with ulcerative colitis (UC) who are found to have high-grade dysplasia, either already had colorectal cancer (CRC) or develop it within a short time. The presence of low-grade dysplasia is also predictive of CRC. Many signaling pathways are shared among IBD and CRC, including cell survival, cell proliferation, angiogenesis, and inflammatory signaling pathways. Current IBD therapeutics target a small subset of molecular drivers of IBD, with many focused on the inflammatory aspect of the pathways. Thus, there is a great need to identify biomarkers of both IBD and CRC, that can be predictive of therapeutic efficacy, disease severity, and predisposition to CRC. In this study, we explored the changes in biomarkers specific for inflammatory, metabolic, and proliferative pathways, to help determine the relevance to both IBD and CRC. Our analysis demonstrated, for the first time in IBD, the loss of the tumor suppressor protein Ras associated family protein 1A (RASSF1A), via epigenetic changes, the hyperactivation of the obligate kinase of the NOD2 pathogen recognition receptor (receptor interacting protein kinase 2 [RIPK2]), the loss of activation of the metabolic kinase, AMP activated protein kinase (AMPKα1), and, lastly, the activation of the transcription factor and kinase Yes associated protein (YAP) kinase, that is involved in proliferation of cells. The expression and activation status of these four elements are mirrored in IBD, CRC, and IBD-CRC patients and, importantly, in matched blood and biopsy samples. The latter would suggest that biomarker analysis can be performed non-invasively, to understand IBD and CRC, without the need for invasive and costly endoscopic analysis. This study, for the first time, illustrates the need to understand IBD or CRC beyond an inflammatory perspective and the value of therapeutics directed to reset altered proliferative and metabolic states within the colon. The use of such therapeutics may truly drive patients into remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsInflammatory Bowel DiseasesColitis, UlcerativeHumansInflammationBiomarkersHyperplasiaRisk Factors

Stichwörter der Autor:innen

AMPKCRCIBDRASSF1ARIPK2YAPdextran sulphate sodiuminsulinmetforminresveratrol

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
  • Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
  • Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
  • Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
  • Department of Pharmacology, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
  • Cardiovascular Research Centre, Faculty of Medicine & Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.

ORCID-Profile: Mohamed Salla, Justine Lai, Heather Armstrong, Jason R B Dyck, Aducio Thiesen, Eytan Wine, Levinus A Dieleman, Shairaz Baksh

Förderung

  • Alberta Innovates
  • Alberta Innovates-Health solutions cancer CRIO

Zitieren

APA

Salla, M., Guo, J., Joshi, H., Gordon, M., Dooky, H., Lai, J., Capicio, S., Armstrong, H., Valcheva, R., Dyck, J. R. B., Thiesen, A., Wine, E., Dieleman, L. A., & Baksh, S. (2023). Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation. International Journal of Molecular Sciences, 24(6), 5967. https://doi.org/10.3390/ijms24065967

Vancouver

Salla M, Guo J, Joshi H, Gordon M, Dooky H, Lai J, et al. Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation. International Journal of Molecular Sciences. 2023;24(6):5967. doi:10.3390/ijms24065967

BibTeX
@article{Salla2023,
  author = {Salla, Mohamed and Guo, Jimmy and Joshi, Harshad and Gordon, Marilyn and Dooky, Hitesh and Lai, Justine and Capicio, Samantha and Armstrong, Heather and Valcheva, Rosica and Dyck, Jason R B and Thiesen, Aducio and Wine, Eytan and Dieleman, Levinus A and Baksh, Shairaz},
  title = {Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5967},
  doi = {10.3390/ijms24065967}
}
Kostenlos starten →